23andMe, the popular DNA testing company, has launched an investigation after client information was listed for sale on a cybercrime forum this week.
On Oct. 1, a post was published on the forum with a link to a sample of allegedly “20 million pieces of data” from the genetic testing company, claiming that it was “the most valuable data you’ll ever see.” The first leak included 1 million lines of data, but on Oct. 4, the threat actor began offering bulk data profiles ranging from $1 to $10 per account in batches of 100, 1,000, 10,000, and 100,000 profiles.
The information leaked in the breach includes names, usernames, profile photos, gender, birthdays, geographical location, and genetic ancestry results.
Scientists testing a new method of sequencing single cells have unexpectedly changed our understanding of the rules of genetics.
The genome of a protist has revealed a seemingly unique divergence in the DNA code signaling the end of a gene, suggesting the need for further research to better understand this group of diverse organisms.
Dr. Jamie McGowan, a postdoctoral scientist at the Earlham Institute, analyzed the genome sequence of a microscopic organism—a protist—isolated from a freshwater pond at Oxford University Parks. The research was published in PLoS Genetics.
Research shows that 20th-century commercial whaling has left a mark on the genetic diversity of surviving whales, emphasizing the importance of understanding and conserving their genetic history.
Commercial whaling in the 20th century decimated populations of large whales but also appears to have had a lasting impact on the genetic diversity of today’s surviving whales, new research from Oregon State University shows.
Grass may transfer genes from their neighbors in the same way genetically modified crops are made, a new study has revealed.
Research, led by the University of Sheffield, is the first to show the frequency at which grasses incorporate DNA from other species into their genomes through a process known as lateral gene transfer.
The stolen genetic secrets give them an evolutionary advantage by allowing them to grow faster, bigger or stronger and adapt to new environments quicker.
Tina Woods, serving as Healthy Longevity Champion for the National Innovation Center for Aging, sets forth her vision for a blueprint for healthy longevity for all. Her emphasis is on reaping the “longevity dividend” and achieving five additional years of healthy life expectancy while reducing health and wellbeing inequality. Woods elaborates on the role of emerging technologies like AI, machine learning, and advanced data analysis in comprehending and influencing biological systems related to aging. She also underscores the crucial role of lifestyle changes and the consideration of socio-economic factors in increasing lifespan. The talk also explores the burgeoning field of emotion AI and its application in developing environments for better health outcomes, with a mention of “Longevity Cities,” starting with a trial in Newcastle. In closing, Woods mentions the development of a framework for incentivizing businesses through measurement of their contribution to health in three areas: workforce health, consumer health through products and services, and community health. Woods envisions a future where businesses impacting health negatively are disincentivized, and concludes with the hope that the UK’s healthy longevity innovation mission can harness longevity science and data innovation to improve life expectancy.
00:00:00 — Introduction, National Innovation Center for Aging. 00:00:56 — Discussion on stagnating life expectancy and UK’s life sciences vision. 00:03:50 — Technological breakthroughs (including AI) in analyzing biological systems. 00:06:22 — Understanding what maintains health & wellbeing. 00:08:30 — Hype, hope, important of purpose. 00:10:00 — Psychological aging and “brain capital.“ 00:13:15 — Ageism — a barrier to progress in the field of aging. 00:15:46 — Health data, AI and wearables. 00:18:44 — Prevention is key, Health is an asset to invest in. 00:19:13 — Longevity Cities. 00:21:19 — Business for Health and industry incentives. 00:23:13 — Closing.
About the Speaker: Tina Woods is a social entrepreneur and system architect with a focus on health innovation at the intersection of science, technology, policy, and investment. She is the Founder and CEO of Collider Health and Business for Health, driving systemic change for better health through these platforms. She contributes to key UK health strategies and initiatives, like UKRI’s Healthy Ageing Industrial Strategy, and served as the Healthy Longevity Champion for the National Innovation Centre for Ageing. Woods has made significant contributions to AI in health and care, co-leading the Quantum Healthy Longevity Innovation Mission and authoring the book, “Live Longer with AI.” Previously, she served as the director of the All Party Parliamentary Group for Longevity secretariat. Woods is also the CEO & Founder of Collider Science, a social enterprise that encourages young people’s interest in science and technology. She holds a degree in genetics from Cornell University and an MBA from Bayes Business School in London.
WEHI researchers have identified a small change in the sequence of a particular gene that increases the likelihood of inflammation in carriers. | Genetics And Genomics.
The investigators carried out animal trials with the engineered AsCas12f system, partnering it with other genes and administering it to live mice. The encouraging results indicated that engineered AsCas12f has the potential to be used for human gene therapies, such as treating hemophilia.
The team discovered numerous potentially effective combinations for engineering an improved AsCas12f gene-editing system, and acknowledged the possibility that the selected mutations may not have been the most optimal of all the available mixes. As a next step, computational modeling or machine learning could be used to sift through the combinations and predict which might offer even better improvements.
And as the authors noted, by applying the same approach to other Cas enzymes, it may be possible to generate efficient genome-editing enzymes capable of targeting a wide range of genes. “The compact size of AsCas12f offers an attractive feature for AAV-deliverable gRNA and partner genes, such as base editors and epigenome modifiers. Therefore, our newly engineered AsCas12f systems could be a promising genome-editing platform … Moreover, with suitable adaptations to the evaluation system, this approach can be applied to enzymes beyond the scope of genome editing.”
The tool — called the Cryosection Histopathology Assessment and Review Machine, or CHARM — studies images to quickly pick out the genetic profile of a kind of tumor called glioma, a process that currently takes days or weeks.
Discover how THALES collaborates with the CNRS to identify new genetic markers leading to the development of pediatric cancers, thereby contributing to the improvement of patient care.
